Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2007-7-25
pubmed:abstractText
Adiponectin possesses anti-inflammatory, insulin-sensitizing and anti-atherosclerotic properties. The aim of this study was to assess the levels of serum adiponectin in patients with chronic viral hepatitis C and B and correlate them with parameters exploring insulin resistance and indices of chronic liver disease. Seventy-two patients with chronic hepatitis C virus (HCV) infection and 73 patients with chronic hepatitis B virus (HBV) infection, matched for age and sex, were studied. All individuals were examined for serum concentrations of adiponectin, insulin, C-peptide and homeostasis model assessment for insulin resistance (HOMA-IR). Viral parameters and liver histology were also evaluated. Serum adiponectin levels were significantly higher in HCV compared with HBV-infected patients. Correlation analysis in the whole group demonstrated that serum adiponectin was positively correlated with aspartate aminotransferase, alkaline phosphatase, globulins, high-density lipoprotein cholesterol and staging score, while it was negatively correlated with body mass index, insulin, C-peptide and HOMA-IR. Logistic regression analysis identified type of infection (HCV vs HBV), alcohol consumption more than 25 g daily, serum total globulin and low C-peptide as significant predictive variables associated with high adiponectin levels. Higher levels of serum adiponectin in HCV compared with HBV patients could have a role in the slower disease progression of chronic HCV infection. In addition, alcohol intake more than 25 g daily seems to be a significant predictor for hyperadiponectinaemia in patients with chronic viral hepatitis C or B. Finally, in this study, a clear positive association between adiponectin and hepatic necroinflammation or staging score was not found.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1352-0504
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
577-83
pubmed:meshHeading
pubmed-meshheading:17650292-Adiponectin, pubmed-meshheading:17650292-Alkaline Phosphatase, pubmed-meshheading:17650292-Aspartate Aminotransferases, pubmed-meshheading:17650292-Biopsy, pubmed-meshheading:17650292-C-Reactive Protein, pubmed-meshheading:17650292-Cholesterol, pubmed-meshheading:17650292-DNA, Viral, pubmed-meshheading:17650292-Female, pubmed-meshheading:17650292-Globulins, pubmed-meshheading:17650292-Hepacivirus, pubmed-meshheading:17650292-Hepatitis B, Chronic, pubmed-meshheading:17650292-Hepatitis B virus, pubmed-meshheading:17650292-Hepatitis C, Chronic, pubmed-meshheading:17650292-Histocytochemistry, pubmed-meshheading:17650292-Humans, pubmed-meshheading:17650292-Insulin Resistance, pubmed-meshheading:17650292-Male, pubmed-meshheading:17650292-Middle Aged, pubmed-meshheading:17650292-RNA, Viral, pubmed-meshheading:17650292-Triglycerides, pubmed-meshheading:17650292-gamma-Glutamyltransferase
pubmed:year
2007
pubmed:articleTitle
Serum adiponectin in chronic hepatitis C and B.
pubmed:affiliation
Department of Internal Medicine, Patras University Hospital, Patras, Greece. dsiagris@altecnet.gr
pubmed:publicationType
Journal Article